Trial Profile
Effect of the angiotensin II receptor antagonist irbesartan on insulin sensitivity and metabolic profile in patients with chronic heart failure
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Mar 2013
Price :
$35
*
At a glance
- Drugs Irbesartan (Primary)
- Indications Chronic heart failure
- Focus Biomarker; Pharmacodynamics
- Acronyms IRIS-HF
- 31 Mar 2009 Results were presented at the 58th Annual Scientific Session of the American College of Cardiology (ACC-2009).
- 30 Aug 2008 Results were presented at ESC Congress 2008: Annual Congress of the European Society of Cardiology.
- 30 Oct 2007 Status changed from recruiting to completed.